Biological Products, (No Diagnostic Substances) · DE · CIK 1628171
Revolution Medicines develops novel therapies for cancer treatment
Comparable business profile · signals at a glance
In the last 90 days: 1 sold $1.0M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 29, 2026 | Patel SushilDirector | Sell | 1,100 | $185.90 | $204K |
| Jun 29, 2026 | Patel SushilDirector | Sell | 881 | $192.61 | $170K |
| Jun 29, 2026 | Patel SushilDirector | Sell | 900 | $184.59 | $166K |
| Jun 29, 2026 | Patel SushilDirector | Sell | 858 | $186.92 | $160K |
| Jun 29, 2026 | Patel SushilDirector | Sell | 600 | $190.54 | $114K |
| Jun 29, 2026 | Patel SushilDirector | Sell | 541 | $191.87 | $104K |
| Jun 29, 2026 | Patel SushilDirector | Sell | 300 | $187.83 | $56K |
| Jun 29, 2026 | Patel SushilDirector | Sell | 300 | $183.17 | $55K |
| Jun 29, 2026 | Patel SushilDirector | Sell | 100 | $188.57 | $19K |
| Mar 25, 2026 | Mancini AnthonySee Remarks | Sell | 21,086 | $95.49 | $2.0M |
| Mar 25, 2026 | Mancini AnthonySee Remarks | Sell | 11,036 | $96.43 | $1.1M |
| Mar 25, 2026 | Mancini AnthonySee Remarks | Sell | 3,128 | $94.16 | $295K |
| Mar 25, 2026 | Mancini AnthonySee Remarks | Sell | 1,800 | $93.22 | $168K |
| Mar 25, 2026 | Mancini AnthonySee Remarks | Sell | 400 | $97.21 | $39K |
| Mar 19, 2026 | Cislini JeffGeneral Counsel | Sell | 1,163 | $97.44 | $113K |
| Mar 17, 2026 | Goldsmith Mark ASee Remarks | Sell | 12,871 | $99.48 | $1.3M |
| Mar 17, 2026 | Horn Margaret AChief Operating Officer | Sell | 4,583 | $99.48 | $456K |
| Mar 17, 2026 | Kelsey Stephen MichaelSee Remarks | Sell | 4,302 | $99.48 | $428K |
| Mar 17, 2026 | Anders JackChief Financial Officer | Sell | 2,753 | $99.48 | $274K |
| Mar 17, 2026 | Wei LinChief Medical Officer | Sell | 2,073 | $99.48 | $206K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.